HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target
HC Wainwright maintains Buy rating on Monopar Therapeutics.
HC Wainwright & Co. analyst Andres Y.
Maldonado reiterates Monopar Therapeutics (NASDAQ: MNPR ) with a Buy and maintains $105 price target.